Ascentage Pharma (AAPG) said Monday that two of its drug candidates, lisaftoclax and olverembatinib, were included in the 2025 Chinese Society of Clinical Oncology Guidelines.
The company said lisaftoclax is first recommended in the CSCO guidelines as a potential treatment for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
The investigational drug is currently under priority review in China following a November 2024 new drug application, Ascentage said.
Olverembatinib received an upgraded recommendation for use in children with leukemia and retained several existing recommendations for adult leukemia treatment, according to the company.
Ascentage said the drug remains part of China's national reimbursement drug list and is co-marketed in the country with Innovent Biologics.
The investigational drugs have not been approved in the US, Ascentage added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。